Shanghai Pharmaceuticals Holding Co Ltd (SHG:601607) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Pharmaceuticals Holding Co Ltd (601607)
Shanghai Pharmaceuticals Holding Co Ltd (SHG:601607) has a market capitalization of $6.93 Billion (CN¥47.39 Billion) as of April 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #2698 globally and #329 in its home market, demonstrating a -0.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Pharmaceuticals Holding Co Ltd's stock price CN¥16.99 by its total outstanding shares 2789289105 (2.79 Billion).
Shanghai Pharmaceuticals Holding Co Ltd Market Cap History: 2015 to 2026
Shanghai Pharmaceuticals Holding Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $6.86 Billion to $6.93 Billion (0.48% CAGR).
Shanghai Pharmaceuticals Holding Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Pharmaceuticals Holding Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Shanghai Pharmaceuticals Holding Co Ltd's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.27x
Shanghai Pharmaceuticals Holding Co Ltd's market cap is 1.27 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.85 Billion | $120.76 Billion | $3.20 Billion | 0.06x | 2.14x |
| 2017 | $8.59 Billion | $130.85 Billion | $3.52 Billion | 0.07x | 2.44x |
| 2018 | $6.13 Billion | $159.08 Billion | $3.88 Billion | 0.04x | 1.58x |
| 2019 | $6.78 Billion | $186.57 Billion | $4.08 Billion | 0.04x | 1.66x |
| 2020 | $7.25 Billion | $191.91 Billion | $4.50 Billion | 0.04x | 1.61x |
| 2021 | $7.69 Billion | $215.82 Billion | $5.09 Billion | 0.04x | 1.51x |
| 2022 | $7.06 Billion | $231.98 Billion | $5.62 Billion | 0.03x | 1.26x |
| 2023 | $6.83 Billion | $260.30 Billion | $3.77 Billion | 0.03x | 1.81x |
| 2024 | $8.57 Billion | $275.25 Billion | $4.55 Billion | 0.03x | 1.88x |
| 2025 | $7.29 Billion | $283.58 Billion | $5.72 Billion | 0.03x | 1.27x |
Competitor Companies of 601607 by Market Capitalization
Companies near Shanghai Pharmaceuticals Holding Co Ltd in the global market cap rankings as of April 18, 2026.
Key companies related to Shanghai Pharmaceuticals Holding Co Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #204 globally with a market cap of $106.12 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #366 globally with a market cap of $63.72 Billion USD.
- AmerisourceBergen Corporation (STU:ABG): Ranked #395 globally with a market cap of $59.07 Billion USD ( €50.53 Billion EUR).
- Cardinal Health Inc (NYSE:CAH): Ranked #474 globally with a market cap of $50.36 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #204 | McKesson Corporation | NYSE:MCK | $106.12 Billion | $866.38 |
| #366 | Cencora Inc. | NYSE:COR | $63.72 Billion | $327.56 |
| #395 | AmerisourceBergen Corporation | STU:ABG | $59.07 Billion | €275.90 |
| #474 | Cardinal Health Inc | NYSE:CAH | $50.36 Billion | $213.99 |
Shanghai Pharmaceuticals Holding Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Pharmaceuticals Holding Co Ltd's market cap moved from $6.86 Billion to $ 6.93 Billion, with a yearly change of 0.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥6.93 Billion | -4.87% |
| 2025 | CN¥7.29 Billion | -14.95% |
| 2024 | CN¥8.57 Billion | +25.52% |
| 2023 | CN¥6.83 Billion | -3.34% |
| 2022 | CN¥7.06 Billion | -8.11% |
| 2021 | CN¥7.69 Billion | +6.04% |
| 2020 | CN¥7.25 Billion | +6.96% |
| 2019 | CN¥6.78 Billion | +10.62% |
| 2018 | CN¥6.13 Billion | -28.65% |
| 2017 | CN¥8.59 Billion | +25.33% |
| 2016 | CN¥6.85 Billion | -0.07% |
| 2015 | CN¥6.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Shanghai Pharmaceuticals Holding Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.93 Billion USD |
| MoneyControl | $6.93 Billion USD |
| MarketWatch | $6.93 Billion USD |
| marketcap.company | $6.93 Billion USD |
| Reuters | $6.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric … Read more